T-DXd in HER2-Overexpressing and HER2-Mutated NSCLC: Clinical Trial Data and Insights
Panelists discuss how the evolving treatment landscape for HER2-overexpressing NSCLC, particularly with the introduction of trastuzumab deruxtecan, influences therapeutic strategies and decision-making based on recent clinical trial data.
- (Rahul asks Rohit) Could you provide an overview of the current treatment landscape for HER2-overexpressing NSCLC? What is considered the SOC in various lines of treatment, and how do different therapeutic strategies—such as immunotherapy, chemotherapy, HER2-targeted therapies, and combination approaches—fit into various lines of treatment?
- (Rohit asks Levy, please state indication) T-DXd is approved for HER2-positive (IHC 3+) solid tumors after prior systemic therapy and is in the NCCN guidelines for IHC 3+ occult tumors.How has the emergence of HER2-targeted therapies, particularly trastuzumab deruxtecan, reshaped your treatment approach in HER2-overexpressing NSCLC from biomarker interpretation to treatment decision-making across different lines of therapy?
- With the advent of targeted therapies and personalized medicine, how has the interpretation of biomarker testing, including IHC scoring and disease drivers, shifted your treatment decision-making?
- (Rohit asks Rahul) Can you provide some background on clinical trial data updates with T-DXd in HER2-overexpressing NSCLC?
- DESTINY-Lung01: Cohort 1/1A (Smit E. The Lancet. 2024)
- DESTINY-Lung03 (Planchard D. WCLC 2024. Abstract OA16.05)
- (Rahul asks Levy) Given the data from these trials, how would you incorporate T-DXd into your treatment approach for patients with HER2-overpressing NSCLC?
- In which lines of therapy would you consider T-DXd in HER2-overexpressing NSCLC? (Please feel free to comment on your experience using T-DXd in HER2-mutant NSCLC)
Recent Videos
Related Content
